Measuring health-related quality of life in clinical trials in cystic fibrosis

J Abbott; A Hart; T Havermans; A Matossian; L Goldbeck; C Barreto; A Bergsten-Brucefors; T Besier; P Catastini; F Lupi; D Staab

doi:10.1016/S1569-1993(11)60013-1

Measuring health-related quality of life in clinical trials in cystic fibrosis

J Cyst Fibros. 2011 Jun:10 Suppl 2:S82-5. doi: 10.1016/S1569-1993(11)60013-1.

Authors

J Abbott¹, A Hart, T Havermans, A Matossian, L Goldbeck, C Barreto, A Bergsten-Brucefors, T Besier, P Catastini, F Lupi, D Staab

Affiliation

¹ School of Psychology, University of Central Lancashire, Preston, UK. jabbott@uclan.ac.uk

PMID: 21658648
DOI: 10.1016/S1569-1993(11)60013-1

Abstract

The inclusion of health-related quality of life (HRQoL) as an outcome measure in cystic fibrosis (CF) clinical trials can supply important patient-reported information not captured by other endpoints. Both an appropriate HRQoL measure and sound methodology are required in order to draw valid inferences about treatments and HRQoL. This paper provides the current consensus of the HRQoL Outcomes Group. Particular consideration has been given to the appropriateness of measurement scales, the rationale for including specific domains as endpoints, the importance of considering baseline ceiling effects and the difficulties of data interpretation. Guidance is provided on HRQoL measurement in National and European CF clinical trials.

Publication types

Consensus Development Conference
Research Support, Non-U.S. Gov't

MeSH terms

Clinical Trials as Topic / standards*
Cystic Fibrosis / psychology
Cystic Fibrosis / therapy*
Europe
Humans
Outcome Assessment, Health Care / standards*
Practice Guidelines as Topic*
Quality of Life*